RxDoctor Payments Data

Sarah Trued, NP

Psychiatric/Mental Health · Boise, IDNPI 1881062891

Payments from drug & device makers

$479in general payments, 2019–2025

Across 20 payments — averaging $23.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$160
  • Johnson & Johnson$60
  • Otsuka America Pharmaceutical, Inc.$47
  • Sunovion Pharmaceuticals Inc.$45
  • E.r. Squibb & Sons, L.L.C.$41
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$35
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$45194%
  • Education$276%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$479 in reported general payments places this provider in the 45th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$19,918
Medicare patients
41
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate18$169,606
Invega SustennaPaliperidone Palmitate42$145,762
AristadaAripiprazole Lauroxil20$71,781
FanaptIloperidone20$50,718
Abilify MaintenaAripiprazole20$47,332
Paliperidone ErPaliperidone72$36,756
RexultiBrexpiprazole20$30,447
LatudaLurasidone Hcl12$15,444
Clozapine OdtClozapine32$9,640
DayvigoLemborexant25$8,121
Aripiprazole76$7,679
FetzimaLevomilnacipran Hcl15$7,651
Lurasidone Hcl62$6,570
BelsomraSuvorexant14$6,272
Clozapine44$5,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$60$315,36860 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$47$77,77940 claims
Alkermes, Inc.Aristada$15$71,78120 claims
Vanda Pharmaceuticals Inc.Fanapt$25$50,71820 claims
Sunovion Pharmaceuticals Inc.Latuda$45$15,44412 claims
AbbVieFetzima$18$7,65115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →